icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Ledipasvir / Sofosbuvir plus Ribavirin as highly effective regimen for RF1_2k/1b patients within Georgian national hepatitis C elimination program
 
 
    Reported by Jules Levin
AASLD Liver Meeting Oct 20-24 2017, Washington DC
 
Marine Karchava, Nikoloz Chkhartishvili, Lali Sharvadze, Akaki Abutidze, Natia Dvali, Lana Gatserelia, Lela Dzigua, Natalia Bolokadze, Adam Kotorashvili, Paata Imnadze, Amiran Gamkrelidze, Muazzam Nasrullah, Juliette Morgan, Francisco Averhoff , Tengiz Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia, Hepatology Clinic Hepa, Tbilisi, Georgia, Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia, National Center for Diseases Control and Public Health, Tbilisi, Georgia, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

1106171

1106172

1106173